Markets:

Overview

News

Currencies

International

Treasuries

Azenta, Inc. - Common Stock (NQ:AZTA)

39.16 +1.78 (+4.76%)

Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

3 Reasons to sell AZTA and 1 stock to buy instead

November 02, 2026

What a fantastic six months it’s been for Azenta. Shares of the company have skyrocketed 46.2%, hitting $35.57. This was partly due to its solid quarterly re...

Via StockStory

3 small-cap stocks we find risky

October 30, 2026

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Via StockStory

Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights

October 25, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Moderna, Progyny, Azenta, Oscar Health, and agilon health Shares Skyrocket, What You Need To Know

October 19, 2026

What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter...

Via StockStory

Topics Bonds Government

Azenta, Myriad Genetics, Moderna, Repligen, and PacBio Shares Plummet, What You Need To Know

October 16, 2026

What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp sell-offs as elevated bond yields r...

Via StockStory

Topics Bonds Economy

Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers

October 15, 2026

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Charles River Laboratories (NY...

Via StockStory

2 Volatile Stocks with Promising Prospects and 1 We Ignore

October 15, 2026

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be...

Via StockStory

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

October 06, 2026

From Pomerantz LLP

Via GlobeNewswire

Q2 Earnings Roundup: UFP Technologies (NASDAQ:UFPT) And The Rest Of The Drug Development Inputs & Services Segment

October 05, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how drug development input...

Via StockStory

Drug Development Inputs & Services Stocks Q2 Highlights: West Pharmaceutical Services (NYSE:WST)

September 30, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Economy

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

September 29, 2026

From Pomerantz LLP

Via GlobeNewswire

Rosen Law Firm Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA

September 26, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

September 22, 2026

From Pomerantz LLP

Via GlobeNewswire

Q2 Rundown: 10x Genomics (NASDAQ:TXG) Vs Other Life Sciences Tools & Services Stocks

September 21, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

September 15, 2026

From Pomerantz LLP

Via GlobeNewswire

Q2 Earnings Review: Drug Development Inputs & Services Stocks Led by Azenta (NASDAQ:AZTA)

September 13, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta...

Via StockStory

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

September 08, 2026

From Pomerantz LLP

Via GlobeNewswire

Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks

September 07, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

September 01, 2026

From Pomerantz LLP

Via GlobeNewswire

3 Healthcare Stocks We Keep Off Our Radar

September 01, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

Winners And Losers Of Q2: Illumina (NASDAQ:ILMN) Vs The Rest Of The Life Sciences Tools & Services Stocks

August 25, 2026

Looking back on life sciences tools & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Illumina (NASDAQ:ILMN) and...

Via StockStory

Topics Artificial Intelligence

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA

August 25, 2026

From Pomerantz LLP

Via GlobeNewswire

Stocks making big moves yesterday: Funko, Hims & Hers Health, Azenta, Strategy, and RUM Group

August 25, 2026

Check out the companies making headlines yesterday: Funko (NASDAQ:FNKO): Pop culture collectibles manufacturer Funko (NASDAQ:FNKO) rose by 4.9% on Monday aft...

Via StockStory

Topics Artificial Intelligence Credit Cards

Why Azenta (AZTA) Stock Is Down Today

August 24, 2026

What Happened? Shares of life sciences company Azenta (NASDAQ:AZTA) fell 9.1% in the afternoon session after the company announced, in a regulatory filing, t...

Via StockStory

1 Momentum Stock for Long-Term Investors and 2 We Find Risky

August 19, 2026

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

Via StockStory

Azenta (AZTA) Q3 2026 Earnings Call Transcript ↗

August 11, 2026

Recurring revenue tops 50% as automation investments drive operational progress.

Via The Motley Fool

Topics Earnings

The 5 Most Interesting Analyst Questions From Azenta’s Q2 Earnings Call

August 11, 2026

Azenta’s second quarter showed strong momentum, with results surpassing Wall Street’s expectations for both revenue and earnings. Management attributed this ...

Via StockStory

Topics Earnings

Azenta Q3 Earnings Call Highlights ↗

August 05, 2026

Azenta (NASDAQ:AZTA) reported third-quarter fiscal 2026 revenue that exceeded its outlook, as growth in recurring-revenue businesses and improved Multiomics performance helped offset continued...

Via MarketBeat

Topics Earnings

Azenta (NASDAQ:AZTA) Reports Upbeat Q2 CY2026

August 04, 2026

Life sciences company Azenta (NASDAQ:AZTA) announced better-than-expected revenue in Q2 CY2026, with sales up 12% year on year to $161.2 million. Its non-GAA...

Via StockStory

Azenta (AZTA) Reports Q2: Everything You Need To Know Ahead Of Earnings

August 02, 2026

Life sciences company Azenta (NASDAQ:AZTA) will be reporting results this Tuesday after the bell. Here’s what investors should know. Azenta missed analysts’ ...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Azenta, Inc. - Common Stock (NQ:AZTA)

All News about Azenta, Inc. - Common Stock

Starting at /week.